<DOC>
	<DOCNO>NCT00002907</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness bryostatin 1 treat patient relapsed multiple myeloma .</brief_summary>
	<brief_title>Bryostatin 1 Treating Patients With Relapsed Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine efficacy bryostatin 1 administer 72-hour continuous infusion patient relapse multiple myeloma . II . Determine qualitative quantitative toxic effect bryostatin 1 patient . III . Determine duration response survival follow bryostatin 1 patient . OUTLINE : All patient receive bryostatin 1 72-hour continuous infusion every 2 week disease progression 2 course beyond complete remission . Response assess every 4 course . Patients follow survival . PROJECTED ACCRUAL : A total 15-25 evaluable patient enter study 1.25 year .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Bryostatin 1</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Multiple myeloma stage fail 1 2 prior regimen ( chemotherapy , biologic therapy , , bone marrow transplantation ) Evidence disease progression require Ineligible know treatment higher potential efficacy One follow protein criterion require : Quantifiable Mcomponents IgG , IgA , IgD , IgE Urinary kappa lambda light chain ( BenceJones protein ) excretion Retreatment protocol allow disease relapse complete remission PATIENT CHARACTERISTICS : Age : 18 Performance status : Zubrod 02 Life expectancy : At least 12 week Hematopoietic : Absolute neutrophil count great 1,500/mm3 Platelet count great 50,000/mm3 Hepatic : Bilirubin le 1.5 mg/dL Transaminases le 2.5 time normal Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance least 60 mL/min Cardiovascular : No history impair cardiac status , e.g . : Severe coronary artery disease Cardiomyopathy Congestive heart failure Arrhythmia Other : No known AIDS HIV infection No second malignancy within 5 year except : Adequately treat nonmelanomatous skin cancer Carcinoma situ cervix No pregnant nursing woman Effective contraception require fertile patient 2 month study PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics Chemotherapy : See Disease Characteristics At least 4 week since chemotherapy ( 8 week since mitomycin nitrosoureas ) recover Endocrine therapy : No concurrent steroids Radiotherapy : At least 4 week since radiotherapy recover Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>refractory multiple myeloma</keyword>
</DOC>